Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reissued by stock analysts at Panmure Gordon in a research report issued on Monday. They presently have a GBX 53 ($0.69) target price on the stock. Panmure Gordon’s price target indicates a potential upside of 171.79% from the company’s previous close.

AGY has been the subject of a number of other reports. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 72 ($0.94) price objective on shares of Allergy Therapeutics plc in a report on Friday, July 8th. Numis Securities Ltd assumed coverage on shares of Allergy Therapeutics plc in a report on Wednesday, September 21st. They set a “buy” rating and a GBX 37 ($0.48) price objective for the company.

Allergy Therapeutics plc (LON:AGY) opened at 21.2749 on Monday. Allergy Therapeutics plc has a 52-week low of GBX 17.25 and a 52-week high of GBX 34.82. The firm’s market cap is GBX 125.34 million. The stock has a 50 day moving average price of GBX 18.82 and a 200 day moving average price of GBX 22.15.

In related news, insider Peter Jensen purchased 30,000 shares of Allergy Therapeutics plc stock in a transaction that occurred on Thursday, September 29th. The shares were bought at an average price of GBX 19 ($0.25) per share, for a total transaction of £5,700 ($7,440.28). Also, insider Nicolas Wykeman purchased 150,000 shares of Allergy Therapeutics plc stock in a transaction that occurred on Tuesday, September 27th. The shares were bought at an average price of GBX 18 ($0.23) per share, for a total transaction of £27,000 ($35,243.44).

About Allergy Therapeutics plc

Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.

Receive News & Stock Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related stocks with our FREE daily email newsletter.